Free Trial
NASDAQ:TLRY

Tilray (TLRY) Stock Price, News & Analysis

Tilray logo
$1.17 -0.03 (-2.50%)
Closing price 04:00 PM Eastern
Extended Trading
$1.18 +0.01 (+0.43%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Tilray Stock (NASDAQ:TLRY)

Key Stats

Today's Range
$1.16
$1.21
50-Day Range
$1.16
$1.48
52-Week Range
$1.14
$2.97
Volume
52.64 million shs
Average Volume
45.32 million shs
Market Capitalization
$1.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.70
Consensus Rating
Hold

Company Overview

Tilray Inc is a pharmaceutical and cannabis company founded in 2013 and headquartered in Canada. The company operates in the United States, Europe, Canada, Australia and Latin America. Tilray is known for producing and distributing medical and recreational cannabis products.

Tilray Inc is primarily engaged in the production, research, development and distribution of medical and recreational cannabis products. The company's product portfolio includes dried cannabis, cannabis oil and capsules. Tilray also produces and distributes hemp-based food products, such as hemp hearts and hemp protein powder.

Tilray operates in two segments: Cannabis and Hemp. The Cannabis segment includes medical and adult-use cannabis, and the Hemp segment includes hemp food products and hemp-based CBD products.

The company's stock price has fluctuated significantly over the past few years. Tilray Inc accredits these fluctuations to changing legal landscapes, changing demands of its clients and increasing competition.

Tilray Inc faces significant competition in the cannabis and hemp industries. The company competes with other cannabis producers, such as Canopy Growth Corporation and Aurora Cannabis Inc, as well as with companies that produce hemp-based products, such as Hemp Inc and Charlotte's Web Holdings Inc.

Tilray also faces competition from illegal cannabis producers, particularly in countries where cannabis is still illegal. The company's success will depend on its ability to compete effectively in the legal cannabis and hemp markets and to expand into new markets as legalization continues.

Tilray Inc's growth prospects are closely tied to legalizing cannabis and hemp products. The company has already expanded its operations into several countries where cannabis is legal, such as Canada, the United States and Germany.

Tilray's merger with Aphria Inc in May 2021 has also given the company multiple growth opportunities. The merger created the world's largest cannabis company, with a market capitalization of over $5 billion. The combined company has a strong presence in Canada, Europe and the United States and is well-positioned to benefit from the continued legalization of cannabis and hemp products.

The company's focus on research and development also provides significant growth opportunities. Tilray has a research and development facility in Canada, conducting clinical trials to evaluate the effectiveness of cannabis and hemp-based products for medical purposes.

Tilray Inc faces several risks and challenges, particularly in the current regulatory environment. Cannabis and hemp products are still illegal in many countries, which limits the company's growth opportunities. Even in countries where cannabis is legal, the regulatory environment can be complex and rapidly evolving, creating challenges for the company's operations.

Tilray's success also depends on its ability to compete effectively in a crowded market. The company faces competition from other cannabis and hemp producers, as well as from illegal producers. The company's success will depend on its ability to differentiate itself from its competitors and build a strong brand that resonates with consumers.

Tilray Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
56th Percentile Overall Score

TLRY MarketRank™: 

Tilray scored higher than 56% of companies evaluated by MarketBeat, and ranked 97th out of 147 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tilray has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Tilray has only been the subject of 1 research reports in the past 90 days.

  • Read more about Tilray's stock forecast and price target.
  • Earnings Growth

    Earnings for Tilray are expected to grow in the coming year, from ($0.20) to ($0.10) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Tilray is -3.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Tilray is -3.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Tilray has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Tilray's valuation and earnings.
  • Percentage of Shares Shorted

    12.93% of the outstanding shares of Tilray have been sold short.
  • Short Interest Ratio / Days to Cover

    Tilray has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Tilray has recently increased by 5.82%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Tilray does not currently pay a dividend.

  • Dividend Growth

    Tilray does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.93% of the outstanding shares of Tilray have been sold short.
  • Short Interest Ratio / Days to Cover

    Tilray has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Tilray has recently increased by 5.82%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Tilray has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Consumer Staples companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Tilray this week, compared to 12 articles on an average week.
  • Search Interest

    45 people have searched for TLRY on MarketBeat in the last 30 days. This is an increase of 41% compared to the previous 30 days.
  • MarketBeat Follows

    57 people have added Tilray to their MarketBeat watchlist in the last 30 days. This is an increase of 27% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Tilray insiders have bought more of their company's stock than they have sold. Specifically, they have bought $35,360.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 0.87% of the stock of Tilray is held by insiders.

  • Percentage Held by Institutions

    Only 9.35% of the stock of Tilray is held by institutions.

  • Read more about Tilray's insider trading history.
Receive TLRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tilray and its competitors with MarketBeat's FREE daily newsletter.

TLRY Stock News Headlines

Roth Capital Has Pessimistic View of Tilray FY2025 Earnings
Ignore every stock…
Stocks have been on a tear in 2024… And there’s plenty of great opportunities out there. But one expert says you should forget about EVERY stock for a moment and focus on an even bigger opportunity. The current GOLD supercycle You see, stocks are a dime a dozen for the most part… And, fortunately, they go up more than they go down. But every few decades, precious metals have a systematic supercycle that tends to dwarf the potential of just about anything else. The last time things aligned like this on gold it surged 536%
Why Tilray Stock Plummeted by 42% in 2024
Tilray price target lowered to $1.50 from $2 at TD Cowen
Tilray: Back To Square One (Rating Downgrade)
Tilray (NASDAQ:TLRY) Shares Down 4.1% on Disappointing Earnings
See More Headlines

TLRY Stock Analysis - Frequently Asked Questions

Tilray's stock was trading at $1.33 at the start of the year. Since then, TLRY stock has decreased by 12.0% and is now trading at $1.17.
View the best growth stocks for 2025 here
.

Tilray Inc (NASDAQ:TLRY) released its earnings results on Friday, January, 10th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.07. Tilray's quarterly revenue was up 8.7% compared to the same quarter last year.

Tilray (TLRY) raised $135 million in an initial public offering on Thursday, July 19th 2018. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company served as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.

Tilray's top institutional investors include Madrona Financial Services LLC (0.01%), SG Americas Securities LLC (0.01%), Pallas Capital Advisors LLC (0.01%) and Ameritas Advisory Services LLC. Insiders that own company stock include Brendan Kennedy, Irwin D Simon, Denise M Faltischek, Mitchell Gendel and Carl A Merton.
View institutional ownership trends
.

Shares of TLRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tilray investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), Humana (HUM), Marinus Pharmaceuticals (MRNS), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
1/10/2025
Today
1/21/2025
Next Earnings (Estimated)
4/07/2025
Fiscal Year End
5/31/2025

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:TLRY
Previous Symbol
NASDAQ:TLRY
Fax
N/A
Employees
2,650
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.70
High Stock Price Target
$4.00
Low Stock Price Target
$1.75
Potential Upside/Downside
+130.8%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-244,980,000.00
Pretax Margin
-32.30%

Debt

Sales & Book Value

Annual Sales
$210.48 million
Book Value
$4.14 per share

Miscellaneous

Free Float
929,497,000
Market Cap
$1.10 billion
Optionable
Optionable
Beta
2.08
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:TLRY) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners